DOI QR코드

DOI QR Code

Leucogen Tablets at 60 mg Three Times per Day are Safe and Effective to Control Febrile Neutropenia

  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Cao, Jie (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Qian, Zhi-Ying (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Xu, Xia (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Shi, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Wu, Xue-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Liu, Jin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Wang, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
  • Published : 2014.10.23

Abstract

Purpose: To investigate whether it is safe to use leucogen tablets 60 mg three times per day (180 mg for a day) and whether this regimen could reduce the incidence of febrile neutropenia caused by chemotherapy. Methods: This prospectively designed study focused on the safety and effectiveness of leucogen tablets 60mg three times per day for a group of cancer patients during chemotherapy for mainly lung or gastric cancers. The tablets were administered from 5 days before until the termination of chemotherapy. Neutropenia and other healthcare encounters were defined as events and occurrence was estimated for comparison. Results: We identified 39 patients receiving leucogen tablets 60mg three times per day, including 11 with gastric, 12 with lung and 16 with other sites of cancer. The mean age was 65 (29-75) years and there were 27 male and 12 female patients. The mean duration of leucogen tablets intake was 59 days. Eighteen patients were treated with taxane-based, 4 with irinotecan-based and 17 with other chemotherapy. The incidence of febrile neutropenia was 0%. Twelve patients were found severe neutropenia (grade III/IV), and the duration of severe neutropenia (grade III/IV) was 5 days. Treatment-emergent adverse events were attributable to complications of myelosuppressive chemotherapy or the primary disease (i.e., alopecia, nausea, asthenia, neutropenia, and severe hepatic renal dysfunction). No chemotherapy was delayed and no treatment related death was observed. Conclusions: This study suggested that leucogen tablets 60mg three times per day (180mg for a day) are safe and could be effective for preventing febrile neutropenia in patients with chemotherapy.

Keywords

Leucogen tablets;cancer patients;chemotherapy;febrile neutropenia

Acknowledgement

Supported by : Nanjing science committee

References

  1. Caggiano V, Weiss RV, Rickert TS, et al (2005). Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 103, 1916-24. https://doi.org/10.1002/cncr.20983
  2. Crawford J, Dale DC, Lyman GH (2004). Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer, 100, 228-37. https://doi.org/10.1002/cncr.11882
  3. Lyman GH, Kuderer N, Greene J, Balducci L (1998). The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer, 34, 1857-64. https://doi.org/10.1016/S0959-8049(98)00222-6
  4. Kuderer NM, Dale DC, Crawford J, et al (2006). Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 106, 2258-66. https://doi.org/10.1002/cncr.21847
  5. Kozma CDM, Chia V, Legg L, et al (2012). Trends in Neutropenia-Related Inpatient Events. J Oncol Pract, 8 (3):149-55. https://doi.org/10.1200/JOP.2011.000360
  6. Liu J, Huang XE, Tian GY, et al (2013). Phase II Study on safety and efficacy of Yadanzi$^{(R)}$ (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12. https://doi.org/10.7314/APJCP.2013.14.3.2009
  7. Lyman GH, Kuderer NM (2002). Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs, 62, 65-78. https://doi.org/10.2165/00003495-200262001-00005
  8. Lyman GH, Lyman CH, Agboola O (2005). Risk models for predicting chemotherapy-induced neutropenia. Oncologist, 10, 427-37. https://doi.org/10.1634/theoncologist.10-6-427
  9. Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  10. Morrison VA, Wong M, Hershman D, et al (2007). Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm, 13, 337-48.
  11. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors.
  12. Schilling MBPC, Deeter RG (2011). Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med, 2, 859-66.
  13. Tan HTK, Hurley D, Daniel G, et al (2011). Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin, 27, 79-6. https://doi.org/10.1185/03007995.2010.536527
  14. Weycker D, Malin J, Glass A, et al (2007). Economic burden of chemotherapy-related febrile neutropenia. J Support Oncol, 5, 44-5.
  15. Weycker DMJ, Barron R, Edelsberg J, et al (2011). Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol, 35, 267-74.
  16. Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4. https://doi.org/10.7314/APJCP.2013.14.8.4801
  17. Zhan YP, Huang XE, Cao J, et al (2012). Clinical study on safety and efficacy of Qinin$^{(R)}$ (Cantharidin Sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 4773-6. https://doi.org/10.7314/APJCP.2012.13.9.4773

Cited by

  1. Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.299
  2. Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6765
  3. Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.647
  4. Clinical Investigation in Effect of Riboflavin Sodium Phosphate on Prevention and Treatment for Patients with Radiotherapy Related Esophagitis vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1525
  5. Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3425
  6. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  7. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
  8. Effect of Peripheral Blood CD4 + CD25 + Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2027